Navigation Links
Apollo develops needle-free topical vaccine

SYDNEY, April 30, 2007-Australian bio-discovery company Apollo Life Sciences has released results of preliminary trials of its patented needle-free vaccine technology, which delivers tetanus vaccine transdermally (through the skin) without the need for an injection.

According to Apollo CEO John Priest, the research points the way to the possibility that flu injections may soon be a thing of the past.

"With the winter months fast approaching, people around Australia are considering getting their flu shots, so progress being made by Apollo in developing needle-less vaccines may soon spell the end of the dreaded jab," said Mr Priest.

Mr Priest said the current market for vaccines is worth over US$9 billion annually and - with more than half a billion immunisations given each year by injections - the potential market for needle-free technology is huge.

"The stress of giving vaccines in a needle, particularly to children, and the risk of needle-stick injuries and the re-use of needles in poorer countries can hinder the safe delivery of vaccines. Our needle-free vaccine technology corresponds to a goal of the World Health Organisation to encourage research into safer and simpler forms of vaccination," Mr Priest said.

The trials showed that the Apollo technology can successfully deliver tetanus toxoid vaccine directly through the skin of mice, without needles. The technology has the potential to be applied in the delivery of influenza and measles-mumps-rubella vaccines that are given to Australian children.

Apollo expects to begin human trials of the technology later this year.

"The early tests show great promise for immunisation without needles. Trials show a better antibody (immune) response from our needle-less vaccine than the injected vaccine. Our technology allows simple application without needles, patches, abrasion or ultrasound, which all disrupt the skin," add ed Dr Greg Russell-Jones, Apollo's Science Director.

Apollo's needle-free vaccines would provide a better alternative to injections by:

* Removing the stress of needles - particularly for children;

* Reducing the risk and incidence of needle-stick injuries;

* Reducing the cost of immunisation as the vaccines could be delivered conveniently and easily without medical intervention;

* Being cheaper to store and easier to deploy than injectable vaccines which require refrigeration; and

* Cutting re-use of needles in developing countries, reducing the spread of disease.

Apollo will continue with trials to optimise the tetanus vaccination, and will also investigate the potential of other vaccines.

Apollo has also used its technology to find new ways to deliver other injectable medicines. Last year, the company had notable success with trials on a lotion version of an injected drug for psoriasis.

"We are looking at all the different ways our technology can be used - from anti-inflammatory medicines to the more universal market of vaccines. The tetanus vaccination results pave the way for today's injected vaccines to be rubbed on in the future," said Mr Priest.

For more information: For media enquiries: John Priest, CEO Andrew Huckel Apollo Life Sciences Wilkinson Media 02 9310 1800 / 0419246356 02 8001 8888 / 0402 822 622

www.apollolifesciences.com <http://www.apollolifesciences.com/>

Apollo Life Sciences (ASX: AOP) is a bio-discovery company that has made major breakthroughs in the areas of drug delivery and expression of proteins from human cells. Apollo's combined technologies are expected to lead to more effective and lower cost therapeutics, compared to first generation protein-based drugs.

Fact Sheet

30 April 2007

The importance of ne edle-free vaccines

* The World Health Organization (WHO) estimates that 12 billion injections are given annually, and that 5% of these are immunisations[1]

* The development of needle-free delivery systems for vaccines has been named one of the Grand Challenges in Global Health[2]

* Needles are associated with an increased risk of infection, especially in developing countries, where there are problems with needles being reused and issues with waste management and disposal[3]

* Needle free delivery systems would make vaccines easier to deliver[4]

* Compliance would be significantly improved, with people more likely to avoid an injected vaccine because of fear and pain associated with the needle[5]

* Topical vaccines are cheaper and easier to transport and store non-injected medicines, increasing access to vaccines[6]

* Needle stick injuries are a significant problem in both developed and developing countries. It is estimated that 5 in every 100 injections worldwide result in a needle-stick accident. The introduction of needle-less vaccines would significantly reduce the risk to health care workers[7]

* Some progress has been made with oral polio, cholera and rotavirus vaccines. But diphtheria, tetanus, pertussis, varicella, measles, mumps, rubella, tuberculosis and yellow fever are all still injectable vaccines[8]

* The current market for vaccines is worth approximately $9 billion globally with a 10-12% annual growth rate[9]

* Apollo Life Science is trialling transdermal delivery of different vaccines, and has had success with initial pre-clinical trials of a needle-free tetanus vaccination

Emily Staniforth Wilkinson Media Pty Ltd

P | + 61 2 8001 8888 M | +61 402 349 856 F | +61 -2- 8001 8801

www.wilkinsonmedia.com.au <http://www.wilkinsonmedia.com.au/>

Goldfields House, Suite 1404, Level 14

1 Alfred Street, SYDNEY 2000

ABN: 97 100 455 169

QP Please think of the environment before printing this email

NOTICE This email and any attachments are confidential. They may contain legally privileged information or copyright material. You should not read, copy, use or disclose them without authorisation. If you are not an intended recipient, please contact us at once by return email and then delete both messages. We do not accept liability in connection with computer virus, data corruption, delay, interruption, unauthorised access or unauthorised amendment. This notice should not be removed.

________________________________

________________________________

________________________________

[1] Immunization without needles: reviews, Nature Reviews, Immunology, Volume 5, December 2005, page 905

[2] Grand Challenges in Global Health website: http://www.gcgh.org/Projects/ImproveVaccines/needlefreedelivery/needlefr eedelivery.htm; accessed 24 April 2007

[3] Grand Challenges in Global Health website: http://www.gcgh.org/Projects/ImproveVaccines/needlefreedelivery/needlefr eedelivery.htm; accessed 24 April 2007

[4] Grand Challenges in Global Health website: http://www.gcgh.org/Projects/ImproveVaccines/needlefreedelivery/needlefr eedelivery.htm; accessed 24 April 2007

[5] Grand Challenges in Global Health website: http://www.gcgh.org/Projects/ImproveVaccines/needlefreedelivery/needlefr eedelivery.htm; accessed 24 April 2007< /p>

[6] Grand Challenges in Global Health website: http://www.gcgh.org/Projects/ImproveVaccines/needlefreedelivery/needlefr eedelivery.htm; accessed 24 April 2007

[7] Immunization without needles: reviews, Nature Reviews, Immunology, Volume 5, December 2005, page 905

[8] Immunization without needles: reviews, Nature Reviews, Immunology, Volume 5, December 2005, page 905

[9] www.kaloramainformation.com/biotechnology-market-c57p3/ <http://www.kaloramainformation.com/biotechnology-market-c57p3/> accessed 24 April 2007


'"/>




Related medicine technology :

1. Apollos human proteins boost stem cell research
2. Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine
3. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... ... May 26, 2016- In search of the K. Warriors, Shaolin Institute is ... Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West Interstate 65 ... by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is the 28th ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought ... industry, from leading advocates, associations and industry leaders such as Bioness. , ...
(Date:5/27/2016)... PALMYRA, Wis. (PRWEB) , ... May 27, 2016 ... ... over $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this ... She accepted her award on May 18 at the university’s Student Leadership Awards ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and 3M ... to court documents and SEC filings. A jury has returned a verdict ... Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 ...
Breaking Medicine News(10 mins):